Repare Therapeutics Inc
NASDAQ:RPTX

Watchlist Manager
Repare Therapeutics Inc Logo
Repare Therapeutics Inc
NASDAQ:RPTX
Watchlist
Price: 2.81 USD -5.39% Market Closed
Market Cap: 119.5m USD
Have any thoughts about
Repare Therapeutics Inc?
Write Note

Repare Therapeutics Inc
Operating Expenses

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Repare Therapeutics Inc
Operating Expenses Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Expenses CAGR 3Y CAGR 5Y CAGR 10Y
Repare Therapeutics Inc
NASDAQ:RPTX
Operating Expenses
-$167.4m
CAGR 3-Years
-46%
CAGR 5-Years
-67%
CAGR 10-Years
N/A
B
Bright Minds Biosciences Inc
CNSX:DRUG
Operating Expenses
-CA$7.4m
CAGR 3-Years
-148%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Theratechnologies Inc
TSX:TH
Operating Expenses
-$55.9m
CAGR 3-Years
6%
CAGR 5-Years
-7%
CAGR 10-Years
-14%
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Operating Expenses
-$217.2m
CAGR 3-Years
2%
CAGR 5-Years
-25%
CAGR 10-Years
-30%
Covalon Technologies Ltd
XTSX:COV
Operating Expenses
-CA$17.9m
CAGR 3-Years
10%
CAGR 5-Years
8%
CAGR 10-Years
-18%
Spectral Medical Inc
TSX:EDT
Operating Expenses
-CA$14.9m
CAGR 3-Years
-16%
CAGR 5-Years
-19%
CAGR 10-Years
-1%
No Stocks Found

Repare Therapeutics Inc
Glance View

Market Cap
118.5m USD
Industry
Biotechnology

Repare Therapeutics, Inc. engages in the research, development, and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company is headquartered in St-Laurent, Quebec and currently employs 152 full-time employees. The company went IPO on 2020-06-19. The firm is focused on the development of synthetic lethality (SL) based therapies to patients with cancer. The company uses genome wide, SNIPRx platform to systematically discover and develop targeted cancer therapies focused on genomic instability, including deoxyribonucleic acid (DNA) damage repair. The firm is developing its pipeline of SL product candidates, including its lead product candidate, RP-3500, a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and Rad3-related (ATR) protein kinase for the treatment of solid tumors with specific DNA damage repair-related genomic alterations, including those in the ataxia telangiectasia mutated (ATM) kinase gene. Its preclinical programs include RP-6306 Protein Kinase Membrane-associated tYrosine- and Threonine- specific cdc-2 inhibitory (PKMYT1)kinase SL inhibitor, in advanced solid tumors.

RPTX Intrinsic Value
4.08 USD
Undervaluation 31%
Intrinsic Value
Price

See Also

What is Repare Therapeutics Inc's Operating Expenses?
Operating Expenses
-167.4m USD

Based on the financial report for Dec 31, 2023, Repare Therapeutics Inc's Operating Expenses amounts to -167.4m USD.

What is Repare Therapeutics Inc's Operating Expenses growth rate?
Operating Expenses CAGR 5Y
-67%

Over the last year, the Operating Expenses growth was -10%. The average annual Operating Expenses growth rates for Repare Therapeutics Inc have been -46% over the past three years , -67% over the past five years .

Back to Top